| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | AGM ELISA Kit; Angiomodulin ELISA Kit; FSTL2 ELISA Kit; IBP-7 ELISA Kit; IBP7 ELISA Kit; IBP7_HUMAN ELISA Kit; IGF binding protein 7 ELISA Kit; IGF-binding protein 7 ELISA Kit; IGFBP rP1 ELISA Kit; IGFBP-7 ELISA Kit; IGFBP-rP1 ELISA Kit; IGFBP7 ELISA Kit; IGFBPRP1 ELISA Kit; Insulin like growth factor binding protein 7 ELISA Kit; Insulin-like growth factor-binding protein 7 ELISA Kit; MAC25 ELISA Kit; MAC25 protein ELISA Kit; PGI2 stimulating factor ELISA Kit; PGI2-stimulating factor ELISA Kit; Prostacyclin stimulating factor ELISA Kit; Prostacyclin-stimulating factor ELISA Kit; PSF ELISA Kit; RAMSVPS ELISA Kit; TAF ELISA Kit; Tumor-derived adhesion factor ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, homogenates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
Insulin-like growth factor-binding protein 7 (IGFBP7/MAC25/PSF) is a biological molecule commonly studied in signal transduction research. It is frequently linked to growth-factor signaling that shapes proliferation, differentiation, or tissue remodeling.
UniProt: Q16270
Biological context
Researchers often monitor Insulin-like growth factor-binding protein 7 (IGFBP7/MAC25/PSF) in serum, plasma, and homogenates to better understand themes such as mechanistic biology studies, biomarker-focused profiling, and disease-model research. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Insulin-like growth factor-binding protein 7 (IGFBP7/MAC25/PSF) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, complementary pathway markers and controls appropriate to the biological model) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, Insulin-like growth factor-binding protein 7 (IGFBP7/MAC25/PSF) may also appear under names such as AGM and Angiomodulin. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Insulin-like growth factor-binding protein 7 (IGFBP7/MAC25/PSF) participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
FERMT2 upregulation in CAFs enhances EMT of OSCC and M2 macrophage polarization
X Ma,Oral diseases,2023
The diagnostic value of serum insulin-like growth factor binding protein 7 in gastric cancer
CT Liu,PeerJ,2023
The negative feedback loop of NF-κB/miR-376b/NFKBIZ in septic acute kidney injury
Z Liu,JCI insight,2020
Diagnostic Value of Serum Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Colorectal Cancer
B Qiu,OncoTargets and Therapy,2020
Serum Insulin-Like Growth Factor Binding Protein 7 as a Potential Biomarker in the Diagnosis and Prognosis of Esophagogastric Junction Adenocarcinoma
Liu C T, et al,Gut and Liver,2019